Coloplast Beheer

Beheer criteriumcontroles 4/4

De CEO Coloplast is Kristian Villumsen, benoemd in Dec2018, heeft een ambtstermijn van 5.92 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 22.00M, bestaande uit 55.9% salaris en 44.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.045% van de aandelen van het bedrijf, ter waarde € 12.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.9 jaar en 6.8 jaar.

Belangrijke informatie

Kristian Villumsen

Algemeen directeur

DKK 22.0m

Totale compensatie

Percentage CEO-salaris	55.9%
Dienstverband CEO	5.9yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	5.9yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kristian Villumsen's beloning veranderd ten opzichte van Coloplast's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	DKK 22m	DKK 12m	DKK 5b
Jun 30 2024	n/a	n/a	DKK 5b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	n/a	n/a	DKK 5b
Sep 30 2023	DKK 23m	DKK 12m	DKK 5b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b

Compensatie versus markt: De totale vergoeding ($USD 3.10M ) Kristian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.83M ).

Compensatie versus inkomsten: De vergoeding van Kristian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kristian Villumsen (54 yo)

5.9yrs

Tenure

DKK 22,000,000

Compensatie

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristian Villumsen	President & CEO	5.9yrs	DKK 22.00m	0.045% € 12.1m
Anders Lonning-Skovgaard	Executive VP & CFO	10.3yrs	DKK 11.30m	0.0012% € 317.0k
Allan Rasmussen	Executive Vice President of Global Operations	10.3yrs	DKK 9.90m	0.011% € 3.0m
Nicolai Andersen	Executive Vice President of Chronic Care	no data	DKK 9.50m	geen gegevens
Paul Marcun	Executive Vice President of Growth	5.8yrs	DKK 11.50m	0.014% € 3.6m
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000020% € 5.4k
Aleksandra Dimovska	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Dennis Kaysen	Vice President of Corporate Communications	no data	geen gegevens	geen gegevens
Dorthe Ronnau	Executive Vice President of People & Culture	2.8yrs	geen gegevens	geen gegevens
Alain Morvan	Senior Vice President of Sales Europe	12.6yrs	geen gegevens	geen gegevens
Caroline Rosenstand	Executive Vice President of Voice & Respiratory Care	no data	geen gegevens	geen gegevens
Rasmus Møller	Senior Vice President of Wound & Skin Care	4.2yrs	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CBHD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Barfod	Senior Controller & Employees Representative Director	18.8yrs	DKK 450.00k	0.000020% € 5.4k
Carsten Hellmann	Independent Director	6.9yrs	DKK 690.00k	0.0027% € 717.2k
Lars Rasmussen	Independent Chairman of the Board	5.9yrs	DKK 1.84m	0.0054% € 1.4m
Niels Louis-Hansen	Deputy Chairman	56.8yrs	DKK 938.00k	1.93% € 519.2m
Marianne Wiinholt	Independent Director	3.9yrs	DKK 880.00k	0.00022% € 59.1k
Jette Nygaard-Andersen	Independent Director	8.9yrs	DKK 600.00k	geen gegevens
Nikolaj Gundersen	Employees Representative Director	6.8yrs	DKK 450.00k	geen gegevens
Roland Pedersen	Employees Representative Director	6.8yrs	DKK 450.00k	0.00072% € 193.4k
Annette Bruls	Independent Director	2.9yrs	DKK 600.00k	geen gegevens

6.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CBHD wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Coloplast Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Final dividend of kr.17.00 announced

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023)

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023)

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

New major risk - Financial position

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 21% undervalued after recent price drop

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: €117

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €136

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €128

New 90-day low: €130

New 90-day low - €132

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021